- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
- Device · Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 15
- States / cities
- Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 164
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cystic Fibrosis, Pseudomonas Aeruginosa, Pseudomonas, Lung Infection, Lung Infection Pseudomonal
- Interventions
- AP-PA02, Placebo
- Biological · Other
- Lead sponsor
- Armata Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Tampa, Florida • Boise, Idaho + 16 more
- Conditions
- Cystic Fibrosis
- Interventions
- Denufosol Tetrasodium (INS37217) Inhalation Solution, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 72 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
- Interventions
- Arformoterol Tartrate Inhalation Solution, Tiotropium, Arformoterol and Tiotropium, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 28
- States / cities
- Jasper, Alabama • Tucson, Arizona • San Diego, California + 25 more
- Conditions
- Viral Pneumonia
- Interventions
- SNG001, Placebo
- Drug
- Lead sponsor
- Synairgen Research Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 22
- States / cities
- Sacramento, California • Torrance, California • Naples, Florida + 19 more
- Conditions
- Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
- Interventions
- AP-PA02, Placebo
- Biological · Other
- Lead sponsor
- Armata Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 23
- States / cities
- Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
- Conditions
- Progressive Pulmonary Fibrosis, Interstitial Lung Disease
- Interventions
- Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Drug · Device
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
- Conditions
- Paroxysmal Atrial Fibrillation
- Interventions
- FlecIH-103
- Drug
- Lead sponsor
- InCarda Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 18
- States / cities
- Davis, California • Long Beach, California • Bridgeport, Connecticut + 12 more
- Conditions
- Non Cystic Fibrosis Bronchiectasis
- Interventions
- CMS, Placebo
- Drug · Other
- Lead sponsor
- Zambon SpA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 27
- States / cities
- Newport Beach, California • Palm Springs, California • Reseda, California + 22 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 50
- States / cities
- Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more
- Conditions
- Cystic Fibrosis
- Interventions
- MP-376 (Levofloxacin solution for Inhalation), placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 14
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Asthma
- Interventions
- Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo, Fluticasone/Salmeterol, Budesonide/Formoterol, Budesonide/Albuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 54
- States / cities
- Saraland, Alabama • Chandler, Arizona • Sun City, Arizona + 48 more
- Conditions
- Cystic Fibrosis
- Interventions
- MRT5005, Normal saline
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Denver, Colorado • Gainesville, Florida + 13 more
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
- Interventions
- Iloprost, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 9
- States / cities
- Torrance, California • Jacksonville, Florida • Chicago, Illinois + 6 more
- Conditions
- Cystic Fibrosis
- Interventions
- azithromycin, placebo, Tobramycin solution for inhalation
- Drug
- Lead sponsor
- Bonnie Ramsey
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 45
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
- Conditions
- Asthma
- Interventions
- Levalbuterol, Levalbuterol UDV TID, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- Up to 48 Months
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 46
- States / cities
- Little Rock, Arkansas • Cypress, California • Long Beach, California + 35 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Benralizumab, Placebo
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 84
- States / cities
- Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more
- Conditions
- Asthma
- Interventions
- n-acetylcystine + albuterol, 0.9% saline + albuterol
- Combination Product
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- Aerolized Hydroxychloroquine Sulfate, Placebo
- Drug · Other
- Lead sponsor
- Pulmoquine Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Exercise-Induced Laryngeal Obstruction, Dyspnea During Activity
- Interventions
- Ipratropium Bromide, Normal Saline (Placebo)
- Drug
- Lead sponsor
- Cook Children's Health Care System
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Prosper, Texas
- Conditions
- Asthma
- Interventions
- Fluticasone 250 mg/salmeterol 50 mg, Montelukast 10mg, Theophylline 400 mg, ipratropium
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Asthma
- Interventions
- placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,032 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
- Conditions
- Nausea
- Interventions
- Inhaled isopropyl alcohol, Oral ondansetron, Inhaled normal saline, Oral placebo
- Drug
- Lead sponsor
- Brooke Army Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- San Antonio, Texas